Tighe Reardon - Jun 15, 2021 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Acting Chief Financial Officer, 10%+ Owner
Signature
/s/ Tighe Reardon
Stock symbol
JANX
Transactions as of
Jun 15, 2021
Transactions value $
$10,699,987
Form type
4
Date filed
6/16/2021, 06:11 PM
Previous filing
Jun 10, 2021
Next filing
Jan 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Conversion of derivative security +2.7M 2.7M Jun 15, 2021 See footnote F1, F2
transaction JANX Common Stock Conversion of derivative security +1.15M +42.76% 3.85M Jun 15, 2021 See footnote F1, F2
transaction JANX Common Stock Purchase $10.7M +629K +16.35% $17.00 4.48M Jun 15, 2021 See footnote F2, F3
holding JANX Common Stock 173K Jun 15, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Series A Convertible Preferred Stock Conversion of derivative security -2.11M -100% 0 Jun 15, 2021 Common Stock 2.7M See footnote F1, F2
transaction JANX Series B Convertible Preferred Stock Conversion of derivative security -900K -100% 0 Jun 15, 2021 Common Stock 1.15M See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
F2 Shares are held by Avalon BioVentures SPV I, LP (ABV SPV). ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Mr. Reardon is Chief Financial Officer of Avalon Ventures and shares voting and investment power with respect to the shares held by ABV SPV. Mr. Reardon disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any. if any.
F3 The shares were purchased in the Issuer's initial public offering.